Get the Stockscreener App
1.18
2.48%
-0.03
Inovio Pharmaceuticals Inc stock is traded at $1.18, with a volume of 1.02M.
It is down -2.48% in the last 24 hours and up +7.27% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$1.21
Open:
$1.23
24h Volume:
1.02M
Relative Volume:
0.41
Market Cap:
$97.08M
Revenue:
$65,300
Net Income/Loss:
$-84.93M
P/E Ratio:
-0.6909
EPS:
-1.708
Net Cash Flow:
$-83.57M
1W Performance:
-3.28%
1M Performance:
+7.27%
6M Performance:
-24.36%
1Y Performance:
-18.62%
1-Day Range:
$1.18
$1.25
1-Week Range:
$1.13
$1.25
52-Week Range:
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.18 | 99.55M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
494.25 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
668.56 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
911.60 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.48 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
192.25 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio Pharmaceuticals updates investors on strategy as Nasdaq-listed biotech navigates a challengin - Ad-hoc-news.de
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
INOInovio Pharmaceuticals Inc Volatility & Greeks - Finviz
Inovio stock leans on its pipeline. The market still wants proof. - Ad-hoc-news.de
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Form S-3 Inovio Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
INOVIO PHARMACEUTICALSMAY OFFER UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Inovio Pharmaceuticals (NASDAQ: INO) files $300M shelf registration, notes BLA PDUFA - Stock Titan
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Certain Restricted Stock Units of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-JUL-2026. - marketscreener.com
INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Inovio Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Inovio Pharmaceuticals, Inc.(NasdaqCM: INO) added to Russell 3000E Growth Benchmark - marketscreener.com
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Inovio Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:INO) - TradingView
Price to earnings forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO - TradingView
Price to sales forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO - TradingView
Enterprise value to revenue forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO - TradingView
Inovio Pharmaceuticals, Inc. Actuals & Estimates (BX:GBM) - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
INO stock edges up after hours as partner reports success in cervical dysplasia trial - MSN
Inovio Pharmaceuticals, Inc. Actuals & Estimates (DUS:GBM) - TradingView
Inovio Pharmaceuticals, Inc. Actuals & Estimates (BMV:INO) - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
INO Forecast — Price Target — Prediction for 2027 - TradingView
Inovio Pharmaceuticals Inc (INO) Institutional Confidence - TradingKey
Is Inovio Pharmaceuticals (INO) a High-Stakes Bet Ahead of its October PDUFA Date - Kavout | AI
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Inovio Pharmaceuticals Inc (INO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inovio Pharmaceuticals Inc (INO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inovio Pharmaceuticals Inc (INO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inovio Pharmaceuticals Inc (INO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inovio Pharmaceuticals Inc (INO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Inovio Pharmaceuticals Inc (INO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inovio Pharmaceuticals Inc (INO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Inovio Pharmaceuticals Faces Stock Dilution and Legal Battles - timothysykes.com
Inovio Pharmaceuticals(INO) Stock Options Chain | Quotes & News - Moomoo
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.64%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):